EDSA Stock Forecast 2025-2026
Distance to EDSA Price Targets
EDSA Price Momentum
🤔 Considering Edesa (EDSA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest EDSA Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, EDSA has a bullish consensus with a median price target of $19.00 (ranging from $17.00 to $21.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $2.39, the median forecast implies a 695.0% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Vernon Bernardino at HC Wainwright & Co., projecting a 778.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EDSA Analyst Ratings
EDSA Price Target Range
Latest EDSA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EDSA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $21.00 |
| Aug 20, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $21.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $21.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $21.00 |
| Nov 29, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $21.00 |
| Nov 22, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $10.00 |
| Oct 12, 2023 | Brookline Capital | Kemp Dolliver | Buy | Maintains | $57.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $10.00 |
| May 24, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $16.00 |
| Mar 15, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $16.00 |
| Feb 14, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $16.00 |
| Dec 20, 2021 | HC Wainwright & Co. | Vernon Bernardino | Buy | Initiates | $16.00 |
Edesa Biotech Inc. (EDSA) Competitors
The following stocks are similar to Edesa based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Edesa Biotech Inc. (EDSA) Financial Data
Edesa Biotech Inc. has a market capitalization of $16.71M with a P/E ratio of -1.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -150.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Edesa Biotech Inc. (EDSA) Business Model
About Edesa Biotech Inc.
Develops innovative therapies for dermatological conditions.
Edesa Biotech Inc. operates as a clinical-stage pharmaceutical company, focusing on developing and commercializing therapies for dermatological and gastrointestinal conditions. The company generates revenue by creating novel treatment options and advancing them through clinical trials to gain regulatory approvals, ultimately leading to market sales of their therapies.
Edesa Biotech specializes in small molecule drugs and biologics, targeting conditions with inadequate existing therapies. The company's pipeline includes promising treatments for atopic dermatitis and allergic contact dermatitis, contributing to advancements in skin health. Their commitment to clinical trials and regulatory processes aims to establish a strong market position in the competitive biotech industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Dr. Pardeep Nijhawan FRCPC, M.D.
Country
Canada
IPO Year
2019
Website
www.edesabiotech.comEdesa Biotech Inc. (EDSA) Latest News & Analysis
Edesa Biotech, Inc. (Nasdaq:EDSA) reported its Q4 2024 financial results and business update on February 14, 2025, focusing on immuno-inflammatory disease therapeutics development.
Edesa Biotech's financial results and business update can influence stock performance, signaling potential growth or challenges in its clinical developments and market strategy.
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
1 month agoEdesa Biotech, Inc. sold 834 Series B-1 convertible preferred shares at $10,000 each and 3,468,746 common shares at $1.92 each in a private placement, totaling approximately $8 million.
Edesa Biotech's private placement raises capital for development while insider purchases signal confidence in the company's future, potentially influencing investor sentiment and stock performance.
Edesa Biotech Reports Fiscal Year 2024 Results
3 months agoEdesa Biotech, Inc. (Nasdaq:EDSA) reported its fiscal year 2024 financial results and business update for the year ending September 30, 2024.
Edesa Biotech's financial results and business update signal its current performance and future prospects, impacting stock valuation and investor sentiment in the biopharma sector.
Edesa Biotech (Nasdaq: EDSA) has secured a purchase agreement for up to $5 million from an entity affiliated with CEO Par Nijhawan, including an initial $1.5 million investment.
The $5 million investment from Edesa's CEO signals confidence in the company's potential, potentially boosting stock value and attracting further interest from other investors.
Edesa Biotech Announces Upcoming Conference Schedule
4 months agoEdesa Biotech, Inc. (Nasdaq:EDSA) will participate in several conferences: BIO-Europe (Nov 4-6), Dermatology Drug Development Summit (Nov 12-14), and LSX Investival Showcase (Nov 18, 2024).
Edesa Biotech's participation in key industry conferences highlights its commitment to growth and networking, potentially attracting investors and partnerships, influencing stock performance.
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
6 months agoDr. Pardeep Nijhawan has increased his beneficial ownership of Edesa Biotech, Inc. to over 2% of its outstanding common shares through RSUs and recent transactions.
Dr. Nijhawan's acquisition of over 2% of Edesa's shares signals growing insider confidence, potentially influencing market perception and stock performance.
Frequently Asked Questions About EDSA Stock
What is Edesa Biotech Inc.'s (EDSA) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Edesa Biotech Inc. (EDSA) has a median price target of $19.00. The highest price target is $21.00 and the lowest is $17.00.
Is EDSA stock a good investment in 2025?
According to current analyst ratings, EDSA has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EDSA stock?
Wall Street analysts predict EDSA stock could reach $19.00 in the next 12 months. This represents a 695.0% increase from the current price of $2.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Edesa Biotech Inc.'s business model?
Edesa Biotech Inc. operates as a clinical-stage pharmaceutical company, focusing on developing and commercializing therapies for dermatological and gastrointestinal conditions. The company generates revenue by creating novel treatment options and advancing them through clinical trials to gain regulatory approvals, ultimately leading to market sales of their therapies.
What is the highest forecasted price for EDSA Edesa Biotech Inc.?
The highest price target for EDSA is $21.00 from Vernon Bernardino at HC Wainwright & Co., which represents a 778.7% increase from the current price of $2.39.
What is the lowest forecasted price for EDSA Edesa Biotech Inc.?
The lowest price target for EDSA is $17.00 from at , which represents a 611.3% increase from the current price of $2.39.
What is the overall EDSA consensus from analysts for Edesa Biotech Inc.?
The overall analyst consensus for EDSA is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $19.00.
How accurate are EDSA stock price projections?
Stock price projections, including those for Edesa Biotech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
